Join Growin Stock Community!

Boundless bio, inc.BOLD.US Overview

US StockHealthcare
(No presentation for BOLD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BOLD AI Insights

BOLD Overall Performance

BOLD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BOLD Recent Performance

-0.86%

Boundless bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BOLD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BOLD Key Information

BOLD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BOLD Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Price of BOLD

BOLD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BOLD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
27.84%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.24
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
27.84%

  • When is BOLD's latest earnings report released?

    The most recent financial report for Boundless bio, inc. (BOLD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BOLD's short-term business performance and financial health. For the latest updates on BOLD's earnings releases, visit this page regularly.

  • How much debt does BOLD have?

    As of the end of the reporting period, Boundless bio, inc. (BOLD) had total debt of 49.76M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BOLD have?

    At the end of the period, Boundless bio, inc. (BOLD) held Total Cash and Cash Equivalents of 15.54M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BOLD's EPS continuing to grow?

    According to the past four quarterly reports, Boundless bio, inc. (BOLD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.62. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BOLD?

    Boundless bio, inc. (BOLD)'s Free Cash Flow (FCF) for the period is -10.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 25.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.